Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | July 20, 2005 |
| Target | Guilford Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | MGI Pharma |
| Sellers(s) |
Alta Partners
Nexus Life Science Partners |
| Deal Type | Add-on Acquisition |
FILTER BY
MGI Pharma, Inc., a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products for oncology and acute care applications.
| Deal Context for Buyer | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science | 2 of 2 |
| Type: Add-on Acquisition | 2 of 2 |
| State: Maryland | 1 of 1 |
| Country: United States | 2 of 2 |
| Year: 2005 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-09-03 |
ZYCOS
Lexington, Massachusetts, United States ZYCOS Inc. discovers, researches, and develops new medical entities (NMEs) for treating chronic viral diseases and cancer. |
Buy | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| Deal Context for Seller | # |
|---|---|
| Overall | 23 of 85 |
| Sector: Life Science | 14 of 65 |
| Type: Add-on Acquisition | 15 of 45 |
| State: Maryland | 1 of 3 |
| Country: United States | 21 of 75 |
| Year: 2005 | 4 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-05-18 |
Azelon Pharmaceuticals
West Conshohocken, Pennsylvania, United States Azelon Pharmaceuticals is developing a novel parathyroid hormone (PTH) analog called Ostabolin-C™ for the treatment of osteoporosis which has completed Phase II trials. The Company has other Ostabolin-C™ programs in clinical development. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-08-22 |
Eyetech Pharmaceuticals
Cedar Knolls, New Jersey, United States Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME). |
Sell | $935M |
| Category | Growth Capital Firm |
|---|---|
| Founded | 2001 |
| Size | Small |
| Type | Sector Focused |
Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.
| Deal Context for Seller | # |
|---|---|
| Overall | 4 of 22 |
| Sector: Life Science | 4 of 18 |
| Type: Add-on Acquisition | 2 of 10 |
| State: Maryland | 1 of 1 |
| Country: United States | 4 of 19 |
| Year: 2005 | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-12-21 |
ILEX Oncology
San Antonio, Texas, United States ILEX Oncology, Inc. is a drug development company focused exclusively on the accelerated development of drugs for the treatment and prevention of cancer. ILEX Oncology was founded in 1992 and is based in San Antonio, Texas. |
Sell | $1.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-12-14 |
Abgenix
Fremont, California, United States Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of fully human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. |
Sell | $2.2B |
